20260515 Press Release Q4 & FY26
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 15 May 2026, 12:03 PM IST · BSE ID: 0b962cd5-8c27-4813-bbf4-792c196e4c83
View Original BSE Filing (PDF)
💡
In Simple Terms
Hester Biosciences announced its full-year profits and proposed a dividend of INR 11 per share for its shareholders.
🤖 AI Summary
- Hester Biosciences reported Audited Standalone PAT of INR 521.00 Million for FY26.
- Recommended dividend of INR 11 per equity share of INR 10 each (110%) for FY26.
- Ms. Priya Gandhi re-appointed as Executive Director for 3 years, effective 28 October 2026.
- Statutory Auditors issued an unmodified opinion on the Standalone and Consolidated FY26 financial results.
- Company received marketing and manufacturing licences for H9N2 Avian Influenza vaccine in Q4 FY26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone PAT FY26
INR 521.00 Million
64%
Standalone Revenue from Operations FY26
INR 2,921.36 Million
2%
Consolidated PAT FY26
INR 574.84 Million
99%
Consolidated Revenue from Operations FY26
INR 3,325.99 Million
7%
Dividend per equity share FY26
INR 11
Standalone Poultry Healthcare Revenue FY26
INR 2,060.79 Million
24%
Standalone Animal Healthcare Revenue FY26
INR 818.32 Million
-32%
🏢 How This Affects the Company
The company strengthened its poultry vaccine portfolio by receiving licenses for its H9N2 Avian Influenza vaccine. The Poultry Healthcare Division saw 24% revenue growth in FY26, while the Animal Healthcare Division experienced a 32% decline.
Standalone Profit After Tax increased by 64% to INR 521.00 Million for FY26. Consolidated Profit After Tax increased by 99% to INR 574.84 Million for FY26.
The company capitalised its BSL 3 facility and is optimising certain manufacturing infrastructure to improve utilisation efficiency and cost structure. Ms. Priya Gandhi's re-appointment maintains continuity in strategic direction and operational alignment.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must vote on the proposed dividend and re-appointment of Ms. Priya Gandhi at the upcoming Annual General Meeting.
👤
Who Is Affected
All equity shareholders of Hester Biosciences Limited are affected by the proposed dividend of INR 11 per equity share and the re-appointment of an Executive Director.
🔍
Management Signal
The dividend recommendation signals management's confidence in the company's profitability and commitment to shareholder returns, while director re-appointment indicates continuity.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Date of Annual General Meeting and dividend record date announcements.
Updates on Animal Healthcare Division's performance in Q1 FY27.
Further disclosures on the utilisation efficiency of optimised manufacturing infrastructure.
LOW RISK
Unmodified audit opinion, diversified growth with clear strategies, and continuity in management.
💡 Investor Takeaway
Hester Biosciences reported Standalone PAT of INR 521.00 Million for FY26, a 64% increase, and proposed an INR 11 dividend per share. Consolidated PAT increased by 99% to INR 574.84 Million. The Poultry Healthcare segment grew by 24% in FY26, while Animal Healthcare declined by 32%.
⚖️ Strengths & Concerns
✅ Positives
- Standalone PAT increased by 64% to INR 521.00 Million for FY26, driven by stronger Poultry Healthcare contribution and improved product mix.
- Company recommended an INR 11 per equity share dividend for FY26, signaling consistent shareholder returns based on profitability.
⚠️ Concerns
- Standalone Animal Healthcare Division revenue declined by 32% to INR 818.32 Million in FY26, impacted by delayed government immunisation programs.
- Consolidated profitability in FY26 also benefited from foreign exchange gains and exceptional financial items, indicating some non-operational contributions.
📅 Company Track Record
Hester Biosciences standalone profit after tax for FY26 was INR 521.00 Million, up from INR 318.42 Million in FY25. The company proposed an INR 11 dividend per share for FY26, consistent with its past practice of dividend declarations. The company continues to provide regular financial results disclosures.
Based on publicly available historical data. For context only.